MA46269A - Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r - Google Patents

Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r

Info

Publication number
MA46269A
MA46269A MA046269A MA46269A MA46269A MA 46269 A MA46269 A MA 46269A MA 046269 A MA046269 A MA 046269A MA 46269 A MA46269 A MA 46269A MA 46269 A MA46269 A MA 46269A
Authority
MA
Morocco
Prior art keywords
administering
inhibitor
methods
atopic dermatitis
treating severe
Prior art date
Application number
MA046269A
Other languages
English (en)
Other versions
MA46269B1 (fr
Inventor
Bolanle Akinlade
Ashish Bansal
Neil Graham
Thomas Hultsch
Gianluca Pirozzi
Allen Radin
Brad S Shumel
Xing Sun
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma
Publication of MA46269A publication Critical patent/MA46269A/fr
Publication of MA46269B1 publication Critical patent/MA46269B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA46269A 2017-08-18 2017-09-21 Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r MA46269B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17306081 2017-08-18
PCT/US2017/052772 WO2018057776A1 (fr) 2016-09-22 2017-09-21 Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r

Publications (2)

Publication Number Publication Date
MA46269A true MA46269A (fr) 2019-07-31
MA46269B1 MA46269B1 (fr) 2024-05-31

Family

ID=59772561

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46269A MA46269B1 (fr) 2017-08-18 2017-09-21 Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r

Country Status (4)

Country Link
US (2) US10485844B2 (fr)
MA (1) MA46269B1 (fr)
PT (1) PT3515465T (fr)
WO (1) WO2018057776A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
JP6306588B2 (ja) 2012-08-21 2018-04-04 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
SG11201501011WA (en) 2012-09-07 2015-03-30 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
EP3110848B1 (fr) 2014-02-28 2024-02-14 Regeneron Pharmaceuticals, Inc. Procédés de traitement de l'infection cutanée par l'administration d'un antagoniste de l'il-4r
KR20170081262A (ko) 2014-11-14 2017-07-11 사노피 바이오테크놀로지 Ｉｌ-4ｒ 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법
CN113372446A (zh) 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
HUE067888T2 (hu) 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
PL3515465T3 (pl) 2016-09-22 2024-08-12 Regeneron Pharmaceuticals, Inc. Sposoby leczenia ciężkiego atopowego zapalenia skóry przez podawanie inhibitora il-4r
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
WO2019028367A1 (fr) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de l'oesophagite à éosinophiles active
JP7315545B2 (ja) 2017-10-30 2023-07-26 サノフィ・バイオテクノロジー Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
CN112153982A (zh) * 2018-05-13 2020-12-29 瑞泽恩制药公司 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
US11312778B2 (en) 2018-11-21 2022-04-26 Brian C. Machler Method for treating allergic contact dermatitis
CN111494625B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
CA3132587A1 (fr) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie
MX2022000649A (es) 2019-07-16 2022-06-08 Sanofi Biotechnology Metodos para tratar o prevenir el asma mediante la administracion de un antagonista de il-4r.
CN114173816A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗特应性皮炎的方法
KR20220042217A (ko) 2019-08-05 2022-04-04 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 치료하고 알레르겐-특이적 면역치료요법을 증진시키기 위한 방법
EP3992974A1 (fr) 2020-11-02 2022-05-04 Sanofi Biotechnology Procédés pour le traitement de troubles liés à l'il-13/il-4 identifiés numériquement
EP4073810A1 (fr) 2019-12-09 2022-10-19 Sanofi Biotechnology Méthodes de traitement de troubles associés à l'il-4/il-13 identifiés numériquement
BR112022015363A2 (pt) 2020-03-27 2022-09-20 Regeneron Pharma Uso de um antagonista do receptor de interleucina-4 (il-4r), composição farmacêutica e recipiente para tratar dermatite atópica (da) ou melhorar um parâmetro associado à da em um indivíduo
TWI847170B (zh) * 2021-07-16 2024-07-01 美商德米拉股份有限公司 用於治療異位性皮炎之il-13抗體
KR20240049351A (ko) 2021-08-23 2024-04-16 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
AU2024208789A1 (en) * 2023-01-11 2025-07-24 Regeneron Pharmaceuticals, Inc. Systems and methods for a regulatory-compliant automated assay
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
WO1990005183A1 (fr) 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
WO1992019259A1 (fr) 1991-05-03 1992-11-12 Seragen, Inc. Molecules ciblees sur un recepteur de l'interleukine destinees a traiter l'arthrite inflammatoire
JP3315427B2 (ja) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (fr) 1992-12-29 1994-07-06 Schering-Plough Anticorps monoclonaux contre le récepteur de l'interleukine-4 humain et hydridomes les produisant
ZA946875B (en) 1993-09-07 1995-07-06 Smithkline Beecham Corp Recombinant il4 antibodies useful in treatment of il4 mediated disorders
JP2003524602A (ja) 1998-09-18 2003-08-19 ダイナバックス テクノロジーズ コーポレイション ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物
WO2001092340A2 (fr) 2000-05-26 2001-12-06 Immunex Corporation Utilisation d'antagonistes vis-a-vis de l'interleukine-4 (il-4) et compositions correspondantes
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
KR100572408B1 (ko) 2000-07-26 2006-04-19 가부시키가이샤 호오도 진양성 조성물 및 창상치유촉진 조성물
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
WO2002092125A1 (fr) 2001-05-11 2002-11-21 Novartis Ag Compositions permettant de traiter les troubles associes aux ige
JP4339598B2 (ja) 2001-05-23 2009-10-07 デュオトール アーベー 毒素サブユニットまたはそのフラグメントと共に、又はこれとコンジュゲートされたアレルゲンの経皮投与によるアレルギー反応の抑制
EP2298717B1 (fr) 2001-11-30 2015-10-28 Biogen MA Inc. Anticorps dirigés contre des protéines chimiotactiques
JP2005530490A (ja) 2002-03-29 2005-10-13 シェーリング　コーポレイション インターロイキン−５に対するヒトモノクローナル抗体および方法およびこれを含む組成物
AU2003280324A1 (en) 2002-11-26 2004-06-18 Alk-Abello A/S Pharmaceutical allergen product
PT2000481E (pt) 2003-02-01 2016-06-17 Tanox Inc Anticorpos anti-ige humana de alta afinidade
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
ES2383809T3 (es) 2003-11-07 2012-06-26 Immunex Corporation Anticuerpos que se unen al receptor de interleucina 4
EP1699825A2 (fr) 2003-12-22 2006-09-13 Amgen, Inc. Procedes d'identification d'anticorps fonctionnels
DE602005006758D1 (de) 2004-02-27 2008-06-26 Regeneron Pharma Il-4/il-13-spezifische polypetide und deren therapeutische verwendung
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
WO2006083390A2 (fr) 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxine-3 dans l'oesophagite eosinophile
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
JP4221018B2 (ja) 2006-08-31 2009-02-12 トヨタ自動車株式会社 頭部保護エアバッグ装置
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
PT2769992T (pt) 2006-10-02 2021-03-11 Regeneron Pharma Anticorpos humanos com elevada afinidade para o receptor de il-4 humana
UA102994C2 (ru) 2007-03-22 2013-09-10 Дженентек, Инк. АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧНО СВЯЗЫВАЕТСЯ С IgE/M1' И ИНДУЦИРУЕТ АПОПТОЗ В ЭКСПРЕССИРУЮЩИХ IgE В-КЛЕТКАХ
EP2022507A1 (fr) 2007-08-07 2009-02-11 Universität Hamburg Compositions d'anticorps spécifiques pour les épitopes des lgE, lgG4 et lgA en tant qu'outils pour la création de molécules hypoallergéniques pour l'immunothérapie spécifique
US8637239B2 (en) 2007-11-05 2014-01-28 The Board Of Trustees Of The University Of Illinois Minimally-invasive measurement of esophageal inflammation
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DE202008006598U1 (de) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
WO2010065557A2 (fr) 2008-12-01 2010-06-10 Cincinnati Children's Hospital Medical Center Procédés de détermination de l'efficacité d'un traitement par glucocorticoïde de l'oesophagite à éosinophiles
WO2010120511A2 (fr) 2009-03-31 2010-10-21 Altair Therapeutics, Inc. Procédé de traitement de troubles respiratoires
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
US20110037054A1 (en) 2009-08-17 2011-02-17 Chan-Long Shieh Amoled with cascaded oled structures
AU2010291171B2 (en) 2009-09-07 2015-10-29 Dbv Technologies Method of treating eosinophilic esophagitis
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
EP3970726A1 (fr) 2010-06-24 2022-03-23 ViroPharma Biologics LLC Procédés de traitement de l'inflammation de l' sophage
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
RU2453303C1 (ru) 2010-12-23 2012-06-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения атопического дерматита
EP2661631A4 (fr) 2011-01-06 2014-05-21 Childrens Hosp Medical Center Profils d'expression de cytokine sophagienne dans l' sophagite à éosinophiles
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
AU2012272858B2 (en) 2011-06-21 2017-03-09 Children's Hospital Medical Center Diagnostic methods for eosinophilic esophagitis
US20140303067A1 (en) 2011-10-06 2014-10-09 N.V. Nutricia Treatment of eosinophilic esophagitis
AU2012351342A1 (en) 2011-12-16 2014-07-24 Atopix Therapeutics Limited Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
SG11201404486QA (en) 2012-01-31 2014-11-27 Genentech Inc Anti-ig-e m1' antibodies and methods using same
WO2013155010A1 (fr) 2012-04-09 2013-10-17 Children's Hospital Medical Center Biomarqueurs non invasifs pour l'œsophagite éosinophile
JP6306588B2 (ja) 2012-08-21 2018-04-04 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
SG11201501011WA (en) 2012-09-07 2015-03-30 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
US10132809B2 (en) 2012-10-10 2018-11-20 Rhote Island Hospital Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI757893B (zh) 2013-06-21 2022-03-11 法商賽諾菲生物技術公司 Il-4r拮抗劑用於製造治療鼻息肉症的藥物之用途
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
EP3110848B1 (fr) 2014-02-28 2024-02-14 Regeneron Pharmaceuticals, Inc. Procédés de traitement de l'infection cutanée par l'administration d'un antagoniste de l'il-4r
KR20170081262A (ko) * 2014-11-14 2017-07-11 사노피 바이오테크놀로지 Ｉｌ-4ｒ 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법
MX2018009990A (es) 2016-02-19 2018-12-17 Regeneron Pharma Metodos para mejorar la eficacia de una vacuna mediante la administracion de un antagonista il-4r.
HUE067888T2 (hu) 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
JP7315545B2 (ja) 2017-10-30 2023-07-26 サノフィ・バイオテクノロジー Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
CN112153982A (zh) 2018-05-13 2020-12-29 瑞泽恩制药公司 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
CA3132587A1 (fr) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie
KR20220042217A (ko) 2019-08-05 2022-04-04 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 치료하고 알레르겐-특이적 면역치료요법을 증진시키기 위한 방법
CN114173816A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗特应性皮炎的方法

Also Published As

Publication number Publication date
MA46269B1 (fr) 2024-05-31
US11167004B2 (en) 2021-11-09
WO2018057776A1 (fr) 2018-03-29
US20200246416A1 (en) 2020-08-06
PT3515465T (pt) 2024-03-04
US10485844B2 (en) 2019-11-26
US20180078603A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
MA46269A (fr) Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r
MA52624A (fr) Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
JOP20200115A1 (ar) تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
PH12015502028A1 (en) Ido inhibitors
MX2015017486A (es) Inhibidores de indolamina 2,3-dioxigenasa (dio).
EA033395B1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
MX2015011374A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2020004183A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
EP3347469A4 (fr) Méthodes et compositions pour le traitement du glaucome
EA201790806A1 (ru) Иммунорегулирующие средства
EA201991183A1 (ru) Новые ингибиторы глутаминазы
EA201791874A1 (ru) Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
EA201891468A1 (ru) Композиции и способы для снижения экспрессии tau
MX2017006048A (es) 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetrahidropiridi nas en calidad de inhibidores de bace1 para tratar enfermedad de alzheimer.
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
EP3538189A4 (fr) Compositions, dispositifs et méthodes pour le traitement de conditions médiées par un récepteur des opioides
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EP3313186A4 (fr) Combinaison d'inhibiteurs de lpt-723 et de point de contrôle immunitaire et méthodes de traitement
MX2017015923A (es) Inhibidores de indolamina-2,3-dioxigenasa (ido).